1,106
Participants
Start Date
November 18, 2020
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2026
Magmaris
MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
RECRUITING
Heart Center Segeberger Kliniken, Bad Segeberg
RECRUITING
Herz-und Gefäßzentrum Oberallgäu-Kempten, Kempten
Lead Sponsor
Biotronik AG
INDUSTRY